LY 2300559

Drug Profile

LY 2300559

Alternative Names: LY2300559; mGlu Pot/Cys - Eli Lilly

Latest Information Update: 07 Aug 2012

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antimigraines
  • Mechanism of Action Leukotriene D4 receptor antagonists; Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 16 Jul 2012 Discontinued - Phase-II for Migraine in Puerto Rico (PO)
  • 16 Jul 2012 Discontinued - Phase-II for Migraine in USA (PO)
  • 01 Apr 2012 Eli Lilly completes a phase II trial for Migraine prevention in USA and Puerto Rico (NCT01184508)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top